Xilis Inc. is a biotechnology company based in Durham, North Carolina, dedicated to advancing precision oncology and transforming cancer care. The company's proprietary MicroOrganoSphere (MOS) technology enables the rapid and scalable creation of patient-derived tumor models that accurately reflect the complexity of individual tumors and their microenvironments. This innovative platform facilitates effective drug discovery and development by using AI-driven analytics to inform treatment decisions and streamline clinical trials. Xilis aims to improve patient outcomes by harnessing its MOS technology to enable more personalized therapeutics, ensuring that the right treatments are guided to the right patients at the right time. The company fosters a collaborative and diverse work environment where individuals from various backgrounds contribute to significant advancements in cancer research and care. Xilis values integrity, innovation, and teamwork as it seeks to make impactful changes in the field of oncology.